{
    "clinical_study": {
        "@rank": "112527", 
        "arm_group": [
            {
                "arm_group_label": "Menveo, dose escalating", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Nimenrix, dose escalating", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Invasive meningococcal disease is a worldwide problem with serious repercussions for those\n      affected. Vaccination is recognized as the best way to combat it. The cost of vaccination is\n      prohibitive in many low-resource settings at home and abroad. By harnessing the special\n      immunologic properties of the skin, a dose reduction may be achieved by intradermal\n      administration of the vaccine. The cost savings associated with dose reduction will increase\n      availability of the vaccine."
        }, 
        "brief_title": "Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Meningococcal Disease", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Meningococcal C naive subjects are required to fulfill all of the following criteria:\n\n          -  Age \u2265 30 years\n\n          -  Good health according to the investigator\n\n          -  Willingness and ability to adhere to the study regimen\n\n          -  Able to give informed consent\n\n        Meningococcal C experienced subjects are required to fulfill all of the following\n        criteria:\n\n          -  Age \u2265 18 years\n\n          -  Good health according to the investigator\n\n          -  Willingness and ability to adhere to the study regimen\n\n          -  Able to give informed consent\n\n        Exclusion Criteria:\n\n        Meningococcal C na\u00efve subjects should not have:\n\n          -  Known previous invasive meningococcal infection\n\n          -  Known or suspected previous vaccination against meningococcal disease\n\n          -  Known or suspected allergy against any of the vaccine components\n\n          -  Close contact in the last 60 days with a person known to be Neisseria positive\n\n          -  History of unusual or severe reactions to any previous vaccination\n\n          -  Family history of Guillain-Barr\u00e9 Syndrome\n\n          -  Known or suspected immune deficiency, either congenital or acquired\n\n          -  Administration of plasma or blood products less than three months prior to inclusion\n             in the study\n\n          -  Pregnancy (breastfeeding is allowed)\n\n          -  Fertile female not conforming to prescribed contraceptive use (await first\n             menstruation after vaccination before getting pregnant)\n\n          -  Any infectious disease\n\n          -  Bleeding disorders or use of anticoagulants\n\n          -  Participation as a subject in another trial in the last 3 months\n\n        Meningococcal C experienced subjects should not have:\n\n          -  Known or suspected allergy against any of the vaccine components\n\n          -  Known previous vaccination with a quadrivalent meningococcal vaccine (either\n             conjugate or polysaccharide)\n\n          -  Close contact in the last 60 days with a person known to be Neisseria positive\n\n          -  History of unusual or severe reactions to any previous vaccination\n\n          -  Family history of Guillain-Barr\u00e9 Syndrome\n\n          -  Known or suspected immune deficiency, either congenital or acquired\n\n          -  Administration of plasma or blood products less than three months prior to inclusion\n             in the study\n\n          -  Pregnancy (breastfeeding is allowed)\n\n          -  Fertile female not conforming to prescribed contraceptive use (await first\n             menstruation after vaccination before getting pregnant)\n\n          -  Any infectious disease\n\n          -  Bleeding disorders or use of anticoagulants\n\n          -  Participation as a subject in another trial in the last 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782066", 
            "org_study_id": "MENID-1", 
            "secondary_id": "2012-003085-41"
        }, 
        "intervention": {
            "arm_group_label": [
                "Menveo, dose escalating", 
                "Nimenrix, dose escalating"
            ], 
            "description": "Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.", 
            "intervention_name": "MEN-ACYW135 reduced-dose intradermal administration", 
            "intervention_type": "Biological", 
            "other_name": [
                "Menveo", 
                "Nimenrix"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2013", 
        "location": {
            "contact": {
                "email": "l.g.visser@lumc.nl", 
                "last_name": "Leo Visser, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Leiden", 
                    "country": "Netherlands", 
                    "state": "South-Holland", 
                    "zip": "2333ZA"
                }, 
                "name": "Leiden University Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Emile Jonker, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Leo Visser, MD, PhD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Dose Finding and Reactogenicity of Reduced-dose Intradermal Administration of Two Quadrivalent Meningococcal Conjugate Vaccines (Menveo\u00ae and Nimenrix\u00ae) in Healthy Adults (MENID-1).", 
        "overall_official": {
            "affiliation": "Leiden University Medical Center", 
            "last_name": "Leo Visser, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Seroprotection rate against meningococcal serogroups ACYW135 (anti-meningococcal antibody titre at baseline and 28 days after vaccination)", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782066"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Leiden University Medical Center", 
            "investigator_full_name": "L.G. Visser, MD, PhD", 
            "investigator_title": "Associate professor of Internal Medicine, Senior Consultant Infectious Diseases", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Local and systemic adverse events (subject log and investigator inspection).", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "source": "Leiden University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Leiden University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}